Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital
March 07, 2023 02:00 ET
|
Noema Pharma
Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system disordersNanna Lüneborg, General Partner at Forbion and Rachel Mears, Partner at...
UPDATE -- Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco
January 05, 2023 14:54 ET
|
Noema Pharma
BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members...
Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco
January 05, 2023 08:00 ET
|
Noema Pharma
BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced that members...
Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia
October 18, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food...
Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study
September 06, 2022 08:00 ET
|
Noema Pharma
Study to validate the novel Patient-Reported Electronic Diary designed to more efficiently and accurately measure disease burden associated with trigeminal neuralgiaLIBRATN (NOE-101 Phase 2/3 study in...
Noema Pharma Announces Recruitment of First Patient in Orpheus Phase 2b Study of PDE10A Inhibitor gemlapodect in Adults with Childhood Onset Fluency Disorder
August 04, 2022 08:00 ET
|
Noema Pharma
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line data expected in Q4 2023 BASEL, Switzerland and...
Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder
June 27, 2022 08:00 ET
|
Noema Pharma
Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line data expected in Q4 2023 BASEL, Switzerland and BOSTON,...
Noema Pharma to Attend and Present at BioEquity Europe and UBS Global Healthcare Conference in May 2022
May 06, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, May 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss clinical-stage Biotech company targeting debilitating central nervous system (CNS) indications, today announces Luigi...
Noema Pharma to Attend and Present at Stifel 2022 CNS Days
March 25, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it...
Noema Pharma Appoints Michael Gutch as Chief Financial Officer
February 28, 2022 08:00 ET
|
Noema Pharma
BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of...